Syneron spikes on Q2 earnings that beat Street estimates

Shares of Syneron Medical Ltd. (Nasdaq:ELOS) were up 5% this morning after the company reported before the opening second-quarter earnings and revenue that topped analysts’ estimates.

For the three months ended June 30, the Israeli medical aesthetic devices maker said it earned $11 million, or $0.40 per share, on revenue of $38.2 million compared with earnings of $10.3 million, or $0.37 per share, on revenue of $37.5 million in the prior year quarter.

Analysts polled by Thomson First Call had expected earnings per share of $0.32 on revenue of $37.1 million.

International sales were up 17% over the same period last year.

By late morning, Syneron was at $16.61, up $0.83 from Wednesday’s close. The stock has ranged between $13.35 and $25.50 during the past 52 weeks.

For detailed price information and news stories on Syneron, click ELOS.

For access to the full article, you must be a registered member - it's FREE.

Already a member? Please log in below